Fewer than a tenth of patients that would benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it releases its initial guidance on the medications.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging increased and just availability to GLP-1 medication.
Based on estimates, over two billion are projected to be obese by 2030 if no action is taken.
"The new guidelines affirms that excess weight is a long-term condition that can be addressed with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major hurdles to universal access to the jabs that can assist patients in reducing considerable weight, notes the agency.
Weight-Loss Drug Shortage
Even in the current most favorable scenario, the supply of GLP-1 therapies could only cover about 100 million people – less than 10% of the global need, according to the WHO.
The advice calls on nations and manufacturers to increase availability, via strategies such as patent sharing.
The intellectual property rights on semaglutide – the main component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Drugs Work
GLP-1 drugs mimick a natural hormone to slow digestion, suppress the appetite and enhance satiety so individuals reduce food intake.
Individuals usually see weight reduction after several weeks of starting on the weekly injections.
Studies points to users may put most of the weight back on after a year of halting the treatment, because their typical appetite resume.
Being carrying excess weight elevates your chance for developing health problems, including diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight impacts people in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
